Scientific Advisory Board

see post

Joseph DeAngelo, M.S.

Mr. DeAngelo was a Vice President of Research and Chief Scientific Officer for Apex Bioscience, the US subsidiary of Curacyte AG and a member of Curacyte Vorstand. He was one of the founding scientists of Apex Bioscience and is an expert in yeast biology. Mr. DeAngelo is an inventor of eleven issued patents. He has been active for over ten years in the field of nitric oxide biology and is a well-recognized expert in the field. Under his direction, Apex’s lead product, PHP, a hemoglobin-based nitric oxide scavenger, was developed from pre-phase 1 to phase 3 clinical trials. Mr. DeAngelo received both his undergraduate and graduate training at the Massachusetts Institute of Technology.

David Bramhill, Ph.D.

Dr. Bramhill has more than 20 years of experience in R&D, business development and licensing in biotechnology. He was Associate Director at Merck Research Laboratories for 14 years where he led evaluation of all technology platforms required for discovery and development of therapeutic monoclonal antibodies, including humanized mice and phage display libraries. His team produced HIV proteins for vaccine development and he coordinated a multinational team developing new antibody-eliciting vaccine for HIV (6 locations in US, Europe and Asia). As a director of licensing for RCT, he managed out-licensing programs covering platform technologies, including Pichia yeast expression technology. He completed more than 50 licenses generating multimillion-dollar revenues from 2007-2012. Dr. Bramhill also developed IP strategies and is co-inventor of technologies related to protein engineering and protein expression. He received his M.A. degree from Cambridge University and Ph.D. from Newcastle University in the UK. He completed his post-doctoral fellowship in the laboratory of Nobel laureate Arthur Kornberg at Stanford University.

Fred Winston, Ph.D.

Prof. Winston is a Professor of Genetics at Harvard Medical School. He is an expert in the areas of yeast genetics, transcriptional control, and chromatin structure. Prof. Winston began studies of yeast genetics and molecular biology as a postdoctoral fellow with Dr. Gerald Fink. For over 20 years, his laboratory at Harvard has used yeast genetics to identify and study proteins critical for normal gene expression. These pioneering studies have led to several new insights concerning the roles of general transcription factors, chromatin remodeling complexes, histone proteins, and transcription elongation. Prof. Winston has been advisor for Dr. Motwani’s scientific team at Apex Bioscience and later at BioSavita. He received his Ph.D. in Biology from the Massachusetts Institute of Technology.

Christophe Javaud, Ph.D., M.B.A.

Dr. Javaud is expert in glycobiology. He was co-founder and CEO and Chairman of the Board of Glycode S.A.S. (France), a VC funded innovative startup company focused on generating yeast with humanized glycoengineering to produce homogenous glycosylation of therapeutic products. He successfully closed 2 financing rounds and built a wide network of French and foreign VCs. Dr. Javaud is co- inventor of three patents in glyco-engineering of yeast. He was successful in licensing deals with major international companies. He was responsible for negotiations and management of collaborative projects (FP7, Eurostars, ISI) deals with major biotech/pharma companies such as Ceva santé animale, Lonza, LFB, Novartis, and Merck-Serono.

Dr. Javaud is a successful leader who managed a multidisciplinary team of 20 scientists and managers for Glycode and has a strong knowledge of worldwide biotech and pharma markets. He received his Ph.D. in molecular biotechnology from University of Limoges in France and his executive M.B.A. at HEC School of Management (Paris)/Babson College (Boston) with a focus on entrepreneurship and innovation.  Dr. Javaud is responsible for directing BioSavita’s glycoengineering program.